A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy. Patients will be treated with QAW039, an active comparator, or placebo. This will be a randomized, placebo-controlled, dose-ranging, multi-centre trial.
Inclusion Criteria:
Exclusion Criteria:
CABA, Buenos Aires B8000XAV, Argentina
CABA, Buenos Aires C1122AAK, Argentina
CABA, Buenos Aires C1186ACB, Argentina
CABA, Buenos Aires C1425BEN, Argentina
Bogota, Cundinamarca, Colombia
Ferolles-Attily, France 77150, France
Heraklion - Crete, GR 711 10, Greece
Nagpur - Maharashtra, India 440012, India
Higashiibaraki-gun, Ibaraki 311-3193, Japan
Tsukubo-gun, Okayama-ken 701-0304, Japan
Chiyoda-ku, Tokyo 1020083, Japan
Chuo-ku, Tokyo 103-0027, Japan
Chuo-ku, Tokyo 103-0028, Japan
Edogawa-ku, Tokyo 134-0083, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Minato-ku, Tokyo 108-8606, Japan
Setagaya-ku, Tokyo 158-0097, Japan
Toshima-ku, Tokyo 171-0014, Japan
Fatih / Istanbul, 34098, Turkey (Türkiye)
Yenisehir/Izmir, 35110, Turkey (Türkiye)
Glasgow - Scotland, G12 OYN, United Kingdom